Dr. Inderbir Gill, founding executive director of the USC Institute of Urology and one of the top urologists in the world, is pioneering a novel breakthrough treatment for prostate cancer. Keck Medicine of USC is the first academic medical center in the nation to utilize the FDA-cleared high intensity focused ultrasound (HIFU) surgical ablation system to target and destroy prostate cancer. The energy-based focal ablative technology allows physicians to introduce the HIFU probe into the rectum while the patient is under general anesthetic and aim the ultrasound beam at the prostate, specifically targeting the cancer lesions.
HIFU has all of the makings of precision medicine and it promises to revolutionize the way prostate cancer is treated. – Inderbir Gill, MD, M.Ch.
Benefits of HIFU
- Highly effective
- Limited side effects
- Minimally invasive
- No blood loss
- No radiation
- Outpatient surgery
- Preserves continence and potency
- Quick recovery
Who is eligible?
Eligible patients have low-to-intermediate risk cancer, with localized lesions within a prostate gland of no more than 40 grams in volume, and who already possess strong levels of continence and potency. In general, patients should have organ-confined disease and a prostate-specific antigen (PSA) level under 15-20 ng/ml.
Beating the odds
Prostate cancer is the second leading cause of death among American men. Learn more about what our physicians and researchers are doing to combat that startling statistic by visiting our prostate cancer page.